Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL)
Public ClinicalTrials.gov record NCT00086203. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to assess the efficacy and safety of talabostat and rituximab in patients with advanced CLL who failed to respond, or have progressed following a prior response, to a fludarabine regimen.
Study identification
- NCT ID
- NCT00086203
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Aug 31, 2007
- Last update posted
- Mar 24, 2015
Ends 2007
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arkansas for Medical Science | Little Rock | Arkansas | 72205 | — |
| Ocala Oncology Center | Ocala | Florida | 34474 | — |
| Gulfcoast Oncology Associates | St. Petersburg | Florida | 33705 | — |
| Indiana Oncology/Hematology Consultants | Indianapolis | Indiana | 46202 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Hematology/Oncology Centers of the Northern Rockies | Billings | Montana | 59101 | — |
| Nevada Cancer Institute | Las Vegas | Nevada | 89135 | — |
| Queens Medical Associates, PC | Fresh Meadows | New York | 11365 | — |
| Long Island Jewish Medical Center | New Hyde Park | New York | 11040 | — |
| NYU Medical Center | New York | New York | 10016 | — |
| James P. Wilmot Cancer Center/University of Rochester | Rochester | New York | 14642 | — |
| Raleigh Hematology/Oncology Clinic | Cary | North Carolina | 27511 | — |
| Wake Forest University Health Sciences | Winston-Salem | North Carolina | 27157 | — |
| Cancer Care Associates/Oklahoma City | Oklahoma City | Oklahoma | 73112 | — |
| Cancer Care Associates--Tulsa | Tulsa | Oklahoma | 74136 | — |
| Cancer Centers of the Carolinas | Seneca | South Carolina | 29672 | — |
| Texas Cancer Center/Abilene | Abilene | Texas | 79606-5208 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Virginia Oncology Associates-Lake Wright Cancer Center | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00086203, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 24, 2015 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00086203 live on ClinicalTrials.gov.